Advances in pharmacogenomics of antiretrovirals: An update

Pharmacogenomics

Volumn 8, Issue 9, 2007, Pages 1169-1178

  Ma, Qing ^a   Brazeau, Dan ^a   Forrest, Alan ^a   Morse, Gene D ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antiretroviral therapy; Host factors; Pharmacogenomics; Pharmacokinetics; Response

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN C3; ATAZANAVIR; CYTOCHROME P450 2B6; CYTOCHROME P450 3A5; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; HLA ANTIGEN; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; MULTIDRUG RESISTANCE PROTEIN 1; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA;

ANTIVIRAL ACTIVITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENCY; DRUG TOLERABILITY; DYSLIPIDEMIA; ETHNIC DIFFERENCE; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY TUBULE DISORDER; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS RESISTANCE;

ANTI-RETROVIRAL AGENTS; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 35348890264     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.9.1169     Document Type: Review

References (55)

1. Martin AM, Nolan D, Gaudieri S, Phillips E, Mallal S: Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity Pharmacogenomics 5(6), 643-655(2004).
2. Fox J. Boffito M, Winston A: The clinical implications of antiretroviral pharmacogenomics. Pharmacogenomics 7(4), 587-596 (2006).
3. Ma Q, Okusanya OO, Smith PF et al.: Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin. Drug Metab. Toxicol. 1(3), 473-485 (2005).
4. Riska P, Lamson M, MacGregor T et al.: Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab. Dispos. 27(8), 895-901 (1999).
5. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z: The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Fxp. Ther. 306(1), 287-300 (2003).
6. Klein K, Lang T, Saussele T et al.: Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet. Genomics 15(12), 861-873 (2005).
7. Tong K, He ML, Lin CK et al.: The Implications of a high allelic frequency of CYP2B6 G516T in ethnic Chinese persons. Clin. Infect. Dis. 43(4), 541-542; author reply 542-544 (2006).
8. Wang J, Sonnerborg A, Rane A et al.: Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet. Genomics 16(3), 191-198. (2006).
9. Saitoh A, Fletcher CV, Brundage R et al.: Efavirenz pharmacokinetics in HIV-1 infected children are associated with CYP2B6-G516T polymorphism. J. Acquir. Immune Defic. Syndr. 45(3), 280-285 (2007).
10. Ribaudo HJ, Haas DW, Tierney C et al.: Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin. Infect. Dis. 42(3), 401-407 (2006).
11. Haas DW, Smeaton LM, Shafer RW et al.: Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/ or nelfinavir: an Adult Aids Clinical Trials Group Study. J. Infect. Dis. 192(11), 1931-1942 (2005).
12. Motsinger AA, Ritchie MD, Shafer RW et al.: Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet. Genomics 16(11), 837-845 (2006).
13. Ritchie MD, Haas DW, Motsinger AA et al.: Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin. Infect. Dis. 43(6), 779-782 (2006).
14. Rotger M, Tegude H, Colombo S et al.: Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin. Pharmacol. Ther. 81(4), 557-566 (2007).
15. Rotger M, Colombo S. Furrer H, Decosterd L, Buclin T, Telenti A: Does tenofovir influence efavirenz pharmacokinetics? Antivir. Ther. 12(1), 115-118 (2007).
16. Rotger M, Colombo S, Furrer H et al.: Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics 15(1), 1-5 (2005).
17. Penzak S, Kabuye G, Mugyenyi P et al.: Cytochrome P450 2B6 (CYP2B6) G516T, influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med. 8(2), 86-91 (2007).
18. Haas DW, Bartlett JA, Andersen JW et al.: Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect. Dis. 43(6), 783-786 (2006).
19. Gatanaga H, Yazaki H, Tanuma J et al.: HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 21(2), 264-265 (2007).
20. Littera R, Carcassi C, Masala A et al.: HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 20(12), 1621-1626 (2006).
21. Martin AM, Nolan D, James I et al.: Predisposition to nevirapine hypersensitivity associated with HLA-DRB1 *0101 and abrogated by low. CD4 T-cell counts. AIDS 19(1), 97-99 (2005).
22. Morse GD, Catanzaro LM, Acosta EP: Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy. Lancet Infect. Dis. 6(4), 215-225 (2006).
23. Mouly SJ, Matheny C, Paine MF et al.: Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin. Pharmacol. Ther. 78(6), 605-618 (2005).
24. Josephson F, Allqvist A, Janabi M et al.: CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin. Pharmacol. Ther. 81(5), 708-712 (2007).
25. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV: Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J. Acquir. Immune Defic. Syndr. 42(4), 441-449 (2006).
26. Burger DM, Schwietert HR, Colbers EP, Becker M: The effect of the CYP219*2 heterozygote genotype on the pharmacokinetics of nelfinavir. Br. J. Clin. Pharmacol. 62(2), 250-252 (2006).
27. Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P et al.: Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 21(1), 41-46 (2007).
28. Lankisch TO, Moeblus U, Wehmeier M et al.: Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology 44(5), 1324-1332 (2006).
29. Boyd MA. Srasuebkul P, Ruxrungtham K et al.: Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenet. Genomics 16(5), 321-329 (2006).
30. Ma Q, Brazeau D, Zingman BS et al.: Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics 8(3), 227-235 (2007).
31. Fellay J, Marzolini C, Meaden ER et al.: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359(9300), 30-36 (2002).
32. Verstuyft C, Marcellin F, Morand-Joubert L et al.: Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active anaretroviral therapy. AIDS 19(18), 2127-2131 (2005).
33. Winzer R, Langmann P, Zilly M et al.: No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur. J. Med. Res. 8(12), 531-534 (2003).
34. Lamba J, Strom S, Venkataramanan R et al.: MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin. Pharmacol. Ther. 79(4), 325-338 (2006).
35. Colombo S, Buclin T, Decosterd LA et al.: Orosomucoid (α1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clin. Pharmacol. Ther. 80(1), 307-318 (2006).
36. Hegele RA: Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism. Am J Hum Genet. 69(6), 1161-1177 (2001).
37. Foulkes AS, Wohl DA, Frank I et al.: Associations among race/ ethnicity. ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med. 3(3), E52 (2006).
38. Nolan D. Moore C, Castley A et al.: Tumour necrosis factor-α gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 17(1), 121-123 (2003).
39. Tarr PE, Taffe P, Blelber G et al.: Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J. Infect. Dis. 191(9), 1419-1426 (2005).
40. Fletcher CV, Kawle SP, Kakuda TN et al.: Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-Infected persons. AIDS 14(14), 2137-2144 (2000).
41. Mauai S, Nolan D, Witt C et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359(9308), 727-732 (2002).
42. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S: Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin. Infect. Dis. 43(1), 99-102 (2006).
43. Zucman D, de Truchis P, Majerholc C, Stegman S. Caillat-Zucman S: Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed french HIV population. J. Acquir. Immune Defic. Syndr. 45(1), 1-3 (2007).
44. Martin AM, Nolan D, Gaudieri S et al.: Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl. Acad. Sci. USA 101(12). 4180-4185 (2004).
45. Phillips EJ: Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? Clin. Infect. Dis. 43(1), 103-105 (2006).
46. Kallianpur AR, Hulgan T, Canter JA et al.: Hemochromatosis (HFE) gene mutations and Peripheral neuropathy during antiretroviral therapy. AIDS 20(11), 1503-1513 (2006).
47. Izzedine H, Hulot JS, Villard E et al.: Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J. Infect. Dis. 194(11), 1481-1491 (2006).
48. Ray AS. Cihlar T. Robinson KL et al.: Mechanism of active renal tubular efflux of tenofovir. Antimicrob. Agents. Chemother. 50(10), 3297-3304 (2006).
49. Xie HG. Kim RB, Wood A, Stein CM: Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41, 815-850 (2001).
50. Kim RB, Leake BE Choo, EF et al.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70(2), 189-199 (2001).
51. Schuetz JD, Connelly MC, Sun D et al.: MRP4: A. previously unidentified factor in resistance to nucleoside-based antiviral drags. Nat. Med. 5(9), 1048-1051 (1999).
52. Haas DW. Ribaudo HJ, Kim RB et al.: Pharmacogenetics of efavirenz and central nervous-system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18(18), 3291-2400 (2004).
53. Zucker SD, Qin X, Rooster SD et al.: Mechanism of indinavir-induced hyperbilirubinenda. Proc. Natl. Acad. Sci. USA 98(22). 12671-12676 (2001).
54. Rodriguez Novoa S, Barreiro P, Rendon A et al.: Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C - >T polymorphism at the multidrug resistance gene 1. Clin. Infect. Dis. 42(2), 291-295 (2006).
55. Maher B, Alfirevic A, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M: TNF-α promoter region gone polymorphisms in HIV-positive patients with lipodystrophy. AIDS 16(15), 2013-2018 (2002).